(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally...
Stats | |
---|---|
Šios dienos apimtis | 8.55M |
Vidutinė apimtis | 2.20M |
Rinkos kapitalizacija | 235.50B |
EPS | INR0 ( 2024-04-24 ) |
Kita pelno data | ( INR0 ) 2024-07-25 |
Last Dividend | INR1.200 ( 2023-05-10 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 125.56 |
ATR14 | INR0.883 (0.20%) |
Tūris Koreliacija
Laurus Labs Limited Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Laurus Labs Limited Koreliacija - Valiuta/Žaliavos
Laurus Labs Limited Finansinės ataskaitos
Annual | 2023 |
Pajamos: | INR50.41B |
Bruto pelnas: | INR15.84B (31.42 %) |
EPS: | INR2.98 |
FY | 2023 |
Pajamos: | INR50.41B |
Bruto pelnas: | INR15.84B (31.42 %) |
EPS: | INR2.98 |
FY | 2022 |
Pajamos: | INR60.41B |
Bruto pelnas: | INR32.66B (54.07 %) |
EPS: | INR14.69 |
FY | 2022 |
Pajamos: | INR48.89B |
Bruto pelnas: | INR26.40B (54.01 %) |
EPS: | INR15.42 |
Financial Reports:
No articles found.
Laurus Labs Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0.800 (N/A) |
INR0 (N/A) |
INR1.200 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.300 | 2017-07-06 |
Last Dividend | INR1.200 | 2023-05-10 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | INR7.40 | -- |
Avg. Dividend % Per Year | 0.35% | -- |
Score | 3.34 | -- |
Div. Sustainability Score | 8.01 | |
Div.Growth Potential Score | 5.86 | |
Div. Directional Score | 6.94 | -- |
Year | Amount | Yield |
---|---|---|
2017 | INR0 | 0.00% |
2018 | INR0.300 | 0.30% |
2019 | INR0.300 | 0.39% |
2020 | INR1.300 | 1.77% |
2021 | INR2.00 | 0.57% |
2022 | INR2.00 | 0.38% |
2023 | INR1.200 | 0.32% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
UBL.NS | Dividend Junior | 2023-08-03 | Annually | 17 | 0.27% | |
POLYCAB.NS | Dividend Knight | 2023-06-21 | Annually | 6 | 0.50% | |
JSL.NS | Dividend Junior | 2023-09-15 | Sporadic | 22 | 0.26% | |
DLF.NS | Dividend Junior | 2023-07-28 | Annually | 18 | 0.60% | |
AARON.NS | Dividend Junior | 2023-08-28 | Sporadic | 5 | 0.36% | |
SOUTHBANK.NS | Dividend Junior | 2023-08-17 | Sporadic | 25 | 0.42% | |
MONARCH.NS | Dividend Junior | 2023-09-14 | Annually | 3 | 0.20% | |
HERANBA.NS | Dividend Junior | 2023-08-17 | Annually | 4 | 0.20% | |
BHEL.NS | Dividend Junior | 2023-08-11 | Annually | 21 | 0.26% | |
RAMCOIND.NS | Dividend Junior | 2023-08-02 | Annually | 23 | 0.32% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0318 | 1.500 | 9.36 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0191 | 1.200 | 9.36 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0396 | 1.500 | -0.672 | -1.007 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.232 | 0.800 | 8.84 | 7.07 | [1 - 3] |
quickRatioTTM | 0.584 | 0.800 | -1.272 | -1.017 | [0.8 - 2.5] |
cashRatioTTM | 0.0455 | 1.500 | -0.858 | -1.287 | [0.2 - 2] |
debtRatioTTM | 0.300 | -1.500 | 5.00 | -7.50 | [0 - 0.6] |
interestCoverageTTM | 2.19 | 1.000 | -0.300 | -0.300 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.62 | 2.00 | 6.46 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.62 | 2.00 | 4.69 | 9.38 | [0 - 20] |
debtEquityRatioTTM | 0.612 | -1.500 | 7.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.465 | 1.000 | 5.58 | 5.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0795 | 1.000 | -0.410 | -0.410 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.227 | 1.000 | 9.85 | 9.85 | [0.2 - 2] |
assetTurnoverTTM | 0.601 | 0.800 | 9.33 | 7.46 | [0.5 - 2] |
Total Score | 8.01 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 146.63 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0396 | 2.50 | -0.432 | -1.007 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.62 | 2.00 | 6.46 | 9.38 | [0 - 30] |
dividendYielPercentageTTM | 0.458 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.62 | 2.00 | 6.46 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.518 | 1.500 | 9.88 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.114 | 1.000 | 9.66 | 0 | [0.1 - 0.5] |
Total Score | 5.86 |
Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.